Dulaglutide Ameliorates Intrauterine Adhesion by Suppressing Inflammation and Epithelial–Mesenchymal Transition via Inhibiting the TGF-β/Smad2 Signaling Pathway
Open Access
- 5 July 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (7) , 964
Abstract
Intrauterine adhesion (IUA) is a common gynecological disease with limited therapeutic options. Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) analog with some anti-fibrotic and anti-inflammatory properties; however, its action on IUA remains uncertain. The purpose of the experiments in this study was to explore the effect of dulaglutide on IUA and to elucidate its mechanism to provide new ideas for the clinical treatment of IUA. An IUA mouse model was established via mechanical curettage and inflammation induction; mice received subcutaneous injection with three doses of dulaglutide once a day for two weeks (treatment) or equal amounts of sterile ddH2O (control), and sham-operated mice were treated similarly to the control mice. Mice were sacrificed, and uterine tissues were subjected to hematoxylin and eosin (H&E) and Masson’s trichrome staining for histomorphological and pathological analyses and real-time quantitative polymerase chain reaction (RT-qPCR) and Western blotting (WB) for gene and protein expression analyses. Dulaglutide improved the shape of the uterine cavity, increased endometrial thickness and the number of glands, and significantly reduced the area of collagen fiber deposition in the endometrium. It significantly reduced collagen type I A 1 (COL1A1), interleukin-1beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), C-C motif chemokine ligand 2 (CCL2), F4/80 (macrophage), vimentin and transforming growth factor-beta (TGF-β) mRNA levels and COL1A1, IL-1β, IL-6, TNF-α, F4/80, vimentin, E-cadherin, TGF-β, and p-Smad2 protein expression levels. This study demonstrates that dulaglutide reduces inflammatory responses by inhibiting M1 macrophage polarization and inflammatory factor release and may ameliorate fibrosis by inhibiting epithelial–mesenchymal transition (EMT) via TGF-β/Smad2 signaling.Keywords
Funding Information
- National Natural Science Foundation of China (81960624, 22YF7WA082, 22JR5RA897, 2021LQGR01)
- Science and Technology Program of Gansu Province (81960624, 22YF7WA082, 22JR5RA897, 2021LQGR01)
This publication has 51 references indexed in Scilit:
- Macrophage plasticity, polarization, and function in health and diseaseJournal of Cellular Physiology, 2018
- Discovery, characterization, and clinical development of the glucagon-like peptidesJournal of Clinical Investigation, 2017
- Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosisProgress in Retinal and Eye Research, 2017
- MicroRNA-1291 promotes endometrial fibrosis by regulating the ArhGAP29-RhoA/ROCK1 signaling pathway in a murine modelMolecular Medicine Reports, 2017
- Human amniotic mesenchymal stromal cell transplantation improves endometrial regeneration in rodent models of intrauterine adhesionsCytotherapy, 2017
- Glutamine inhibits CCl4 induced liver fibrosis in mice and TGF-β1 mediated epithelial–mesenchymal transition in mouse hepatocytesFood and Chemical Toxicology, 2016
- MicroRNA-29b regulates TGF-β1-mediated epithelial–mesenchymal transition of retinal pigment epithelial cells by targeting AKT2Experimental Cell Research, 2016
- Resveratrol inhibits epithelial-mesenchymal transition and renal fibrosis by antagonizing the hedgehog signaling pathwayBiochemical Pharmacology, 2014
- The extra‐pancreatic effects of GLP‐1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systemsDiabetes, Obesity and Metabolism, 2014
- Exendin‐4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltrationBritish Journal of Pharmacology, 2014